What is CEL-SCI?
Founded in 1983 and headquartered in Vienna, Virginia, CEL-SCI is dedicated to the research and development of novel immunotherapy products. The company's pipeline targets critical areas including cancer, autoimmune disorders, and infectious diseases, positioning it within a high-impact sector of the biopharmaceutical industry. This latest round of financing is expected to fuel further development and clinical trials.
How much funding has CEL-SCI raised?
CEL-SCI has raised a total of $53.5M across 3 funding rounds:
Stock Offering
$14.7M
Stock Offering
$31.7M
Stock/Share Issuance
$7.2M
Stock Issuance/Offering (2020): $14.7M with participation from Undisclosed
Stock Issuance/Offering (2021): $31.7M, investors not publicly disclosed
Stock/Share Issuance (2026): $7.2M, investors not publicly disclosed
What's next for CEL-SCI?
With a major strategic investment bolstering its resources, CEL-SCI is poised to accelerate its research and development initiatives. The enterprise-level funding suggests a focus on scaling operations and advancing its immunotherapy candidates through critical stages of clinical evaluation. This capital infusion is anticipated to enhance the company's ability to navigate the complex regulatory pathways and bring its innovative treatments to market, potentially impacting a broad range of debilitating diseases.
See full CEL-SCI company page
